Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 3515707

Argyria: microanalytic-morphologic correlation using paraffin-embedded tissue.

S Landas·S M Bonsib·R Ellerbroek·J Fischer
View original source ↗Export metadata ↓

Abstract

Scanning electron microscopes, which have energy dispersive spectroscopy (x-ray microanalysis) capability, can provide accurate identification of the composition of inorganic deposits in tissue. We report a case of florid argyria in which the same deparaffinized 4-micron sections were sequentially examined by light microscopy, scanning electron microscopy, backscattered electron imaging, and x-ray microanalysis to confirm the clinical impression of argyria. We recommend the use of x-ray microanalysis of paraffin-embedded tissue as a simple, rapid and inexpensive means of precise identification of inorganic deposits of heavy elements in tissue sections.

Explore related subjects

Administration, IntranasalAgedArgyriaArteriosclerosisChoroid PlexusElectron Probe MicroanalysisFemaleHistological TechniquesHumansMicroscopy, Electron, ScanningParaffinSilverSilver NitrateCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Landas, S M Bonsib, R Ellerbroek, J Fischer. 1986. Argyria: microanalytic-morphologic correlation using paraffin-embedded tissue.. https://doi.org/10.3109/01913128609014589

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

Nasal drug delivery--evaluation of an in vitro model using porcine nasal mucosa.

An in vitro model for permeation studies using porcine nasal mucosa was developed and evaluated. The viability and integrity of the mucosa were determined by electrophysiological measurements, permeation studies involving 14C-mannitol and D-(2-3H) glucose, histological studies and a biochemical assay. Enzymatic activity in the mucosa was determined by serosal addition of ouabain. Three different types of porcine nasal mucosa (cavity mucosa, natural septum mucosa and dermatomed septum mucosa) were examined. The results showed that cavity mucosa was the most suitable; this type remained viable for up to 8 h after removal. Lower limits for electrophysiological data were defined in order to establish criteria for tissue viability. This in vitro method using porcine nasal mucosa appears potentially valuable as a tool for further permeation and mechanistic studies within nasal drug delivery research.

Administration, Intranasal↗
PubMed1998

Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials.

OBJECTIVE: To determine whether intranasal corticosteroids are superior to oral H1 receptor antagonists (antihistamines) in the treatment of allergic rhinitis. DESIGN: Meta-analysis of randomised controlled trials comparing intranasal corticosteroids with oral antihistamines. SETTING: Randomised controlled trials conducted worldwide and published between 1966 and 1997. SUBJECTS: 2267 subjects with allergic rhinitis in 16 randomised controlled trials. MAIN OUTCOME MEASURES: Nasal blockage, nasal discharge, sneezing, nasal itch, postnasal drip, nasal discomfort, total nasal symptoms, nasal resistance, and eye symptoms and global ratings. Outcomes measured on different scales were combined to determine pooled odds ratios (categorical outcomes) or standardised mean differences (continuous outcomes). Assessment of heterogeneity between studies, and subgroup analyses of eye symptoms, were undertaken. RESULTS: Intranasal corticosteroids produced significantly greater relief than oral antihistamines of nasal blockage (standardised mean difference 0.63, 95% confidence interval - 0.73 to - 0.53), nasal discharge (-0.5, - 0.6 to - 0.4), sneezing (- 0.49, - 0.59 to - 0.39), nasal itch (- 0.38,- 0.49 to - 0.21), postnasal drip (- 0.24,- 0.42 to - 0.06), and total nasal symptoms (- 0.42,- 0.53 to - 0.32), and global ratings gave an odds ratio for deterioration of symptoms of 0.26 (0.08 to 0.8). There were no significant differences between treatments for nasal discomfort, nasal resistance, or eye symptoms. The effects on sneezing, total nasal symptoms, and eye symptoms were significantly heterogeneous between studies. Other combined outcomes were homogeneous between studies. Subgroup analysis of the outcome of eye symptoms suggested that the duration of assessment (averaged mean score over the study period versus mean score at end of study period) might have accounted for the heterogeneity. CONCLUSION: The results of this systematic review, together with data on safety and cost effectiveness, support the use of intranasal corticosteroids over oral antihistamines as first line treatment for allergic rhinitis.

Administration, Intranasal↗
PubMed1998

Intranasal antiplatelet/antithrombotic efficacy of a novel platelet GPIIB/IIIA receptor antagonist DMP755.

This article describes the equivalent antiplatelet/antithrombotic effects of DMP755 at comparable doses by intranasal and i.v. administration but required substantially higher doses with the oral administration route. Antiplatelet and antithrombotic efficacy of DMP755 or its free acid form XV459 were determined in dogs. Arterial thrombosis models were induced either electrolytically (200 microA anodal current) in the carotid artery or mechanically by external clamping of femoral artery along with stenosis, which result in either total occlusive thrombus formation or cyclic flow reduction (CFR), respectively. Either DMP755 or its free acid form, XV459 demonstrated maximal and comparable antiplatelet efficacy at 0.025-0.1 mg/kg, intravenous (i.v.) or intranasal but not oral (PO) in mongrel dogs. The antiplatelet efficacy of DMP755 at 0.1 mg/kg, intranasal, or i.v. was determined in a cross-over design (n=8 in each group). In this study, a comparable and maximal antiplatelet efficacy for DMP755 after intranasal or i.v. was demonstrated suggesting 100% intranasal bioavailability as compared with the modest antiplatelet efficacy at 0.1 mg/kg, p.o. DMP755 administered at 0.1 mg/kg, intranasally or i.v. or at 0.3 mg/kg, p.o. prevented the incidence of electrolytic injury-induced arterial thrombosis in the carotid artery thrombosis model and prevented the incidence of cyclic flow reduction in mechanically injured and stenosed femoral artery. In conclusion, DMP755 has a comparable intranasal and intravenous antiplatelet/antithrombotic profiles along with a significant improvement over its oral profiles. These data also suggest the potential utility of intranasal DMP755 in various acute and chronic thromboembolic disorders. This is the first report of intranasal bioavailability of a glycoprotein receptor antagonist.

Administration, Intranasal↗